| HAL : hal-00282484, version 1 |
| PubMed : 18404201 |
| PubMed Central : 2292130 |
| DOI : 10.1371/journal.pone.0001906 |
| Fiche détaillée | Récupérer au format |
|
|
| PLoS ONE 3, 4 (2008) e1906 |
|
|
|
|
| Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. |
|
|
| Fanny Lanternier 1Annick Cohen-Akenine 2 |
|
|
| AFIRMM Collaboration(s) |
|
|
| (2008) |
|
|
| Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease started during childhood (Group 1, n = 28) with those of patients whose disease started at adult's age (Group 2, n = 114). Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42% and 77% of patients in groups 1 and 2, respectively (p<0.001). 816 c-kit mutation was associated with systemic mastocytosis in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p = 0.0001). Other c-kit activating mutations were found in 23% of patients with mastocytosis' onset before the age of 5, 0% between 6 and 15 years and 2% at adults' age (p<0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the age of disease's onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy. |
|
|
|
|
|
|
|
|
|
|
| 1 : | Service des Maladies Infectieuses et Tropicales |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Necker - Enfants Malades – Université Paris V - Paris Descartes | |
| 2 : | AFIRM network |
| AFIRM | |
| 3 : | Institut de cancérologie et d'immunologie de Marseille (ICIM) |
| CNRS : IFR137 – INSERM : IFR137 – Université de la Méditerranée - Aix-Marseille II | |
| 4 : | Cancérologie |
| INSERM : U599 – Université de la Méditerranée - Aix-Marseille II | |
| 5 : | Université de la Méditerranée - Aix-Marseille 2 |
| Université de la Méditerranée - Aix-Marseille II | |
| 6 : | Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée (LBPA) |
| CNRS : UMR8113 – École normale supérieure de Cachan - ENS Cachan | |
| 7 : | Service de Biochimie |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Lariboisière – IFR6 | |
| 8 : | Service de dermatologie |
| Hôpital Tenon | |
| 9 : | Service de dermatologie |
| Hôpital Purpan | |
| 10 : | Service d'hématologie biologique |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Necker - Enfants Malades – Université Paris V - Paris Descartes | |
| 11 : | Service d'hématologie clinique [Avicenne] |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Avicenne – Université Paris XIII - Paris Nord | |
| 12 : | Service de dermatologie [necker] |
| Hôpital Necker - Enfants Malades – Assistance publique - Hôpitaux de Paris (AP-HP) – Université Paris V - Paris Descartes | |
| 13 : | Service d'anatomie pathologique |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Necker - Enfants Malades – Université Paris V - Paris Descartes | |
| 14 : | Cytokines, hématopoïèse et réponse immune (CHRI) |
| CNRS : UMR8147 – Université Paris V - Paris Descartes | |
|
|
|
|
|
|
|
|
| Domaine | : | Sciences du Vivant/Immunologie |
|
|
| Liste des fichiers attachés à ce document : | |||||
|
|
|
| hal-00282484, version 1 | |
| http://hal.archives-ouvertes.fr/hal-00282484 | |
| oai:hal.archives-ouvertes.fr:hal-00282484 | |
| Contributeur : Michel Arock | |
| Soumis le : Vendredi 18 Juillet 2008, 15:47:37 | |
| Dernière modification le : Lundi 21 Juillet 2008, 01:24:52 | |